entertainment -WSS

entertainment

author：comprehensive 2025-09-06 08:39:48 - browse：19

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Security flaws in third

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

Use doctors trained outside the U.S. to ease the physician shortage

What PEPFAR has meant on the ground in Ukraine

Lupron, used to halt puberty in children, may cause lasting health problems

Pregnancy discrimination could be enabled by AI

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

entertainment

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Skip the lead apron during X

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Roche to buy Carmot Therapeutics, developer of obesity drugs

Jerome Adams on the need for new antivirals for Covid

How Robert F. Kennedy Jr. distorted vaccine science

Trump demands the U.S. pay no more for drugs than other countries … again

Spinal cord stimulation reduces pain in amputees, study finds

Peter Hotez and the public health issue of online harassment

Skip the lead apron during X

focus

Congenital heart disease patients face new threat of heart failure

Being 'nonadherent' patient made me a more empathetic doctor

Crowdfunding for unproven stem cell procedures spreads misinformation

Skip the lead apron during X

Canadians with cystic fibrosis outlive Americans by a decade

Supreme Court wrestles with OxyContin maker's bankruptcy deal

knowledge

focus

hotspot

Wikipedia